A 58-year-old man with Stage 4 CKD (eGFR 22 mL/min/1.73m²) due to diabetic nephropathy presents with fatigue and dyspnea on exertion for 3 months. His hemoglobin is 8.2 g/dL, MCV 78 fL, serum iron 45 µg/dL, ferritin 320 ng/mL, TSAT 18%, and reticulocyte count 0.8%. Serum creatinine is 3.8 mg/dL, phosphate 5.2 mg/dL, calcium 7.8 mg/dL, and PTH 385 pg/mL. He has not received any prior ESA therapy. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has Stage 4 CKD with anemia of chronic kidney disease (CKD-related anemia) complicated by functional iron deficiency. The low reticulocyte count (0.8%, normal 0.5–2.5%) indicates inadequate erythropoietic response, consistent with EPO deficiency and iron limitation. ## Key Diagnostic Features | Finding | Interpretation | |---------|----------------| | Hemoglobin 8.2 g/dL, MCV 78 fL | Microcytic anemia | | Ferritin 320 ng/mL, TSAT 18% | Functional iron deficiency (adequate stores but poor availability) | | Reticulocyte count 0.8% | Blunted erythropoietic response | | eGFR 22 mL/min/1.73m² | Severe renal impairment → EPO deficiency | ## Management Algorithm ```mermaid flowchart TD A[CKD Stage 4 with anemia]:::outcome --> B{Iron status adequate?}:::decision B -->|No: TSAT < 20% or ferritin low| C[Iron repletion first]:::action B -->|Yes: TSAT ≥ 20% and ferritin adequate| D[Proceed to ESA]:::action C --> E[Recheck iron markers in 2-4 weeks]:::action E --> F{Iron replete?}:::decision F -->|Yes| D F -->|No| G[Continue iron supplementation]:::action D --> H[Start ESA: target Hb 10-11 g/dL]:::action H --> I[Avoid Hb > 12 g/dL: increased CV risk]:::urgent ``` **Key Point:** Iron repletion must precede or accompany ESA initiation in functional iron deficiency. TSAT 18% indicates insufficient iron availability for erythropoiesis despite adequate stores. **High-Yield:** KDIGO 2021 guidelines recommend: - Correct iron deficiency (TSAT < 20% or ferritin < 100 ng/mL in dialysis patients) before or concurrent with ESA. - Target hemoglobin 10–11 g/dL in CKD anemia (avoid overcorrection to > 12 g/dL due to increased thromboembolic and cardiovascular risk). - ESA monotherapy without iron repletion will fail. **Clinical Pearl:** Ferritin 320 ng/mL may appear "adequate," but in CKD, ferritin is an acute-phase reactant and unreliable alone. TSAT 18% is the more sensitive marker of functional iron deficiency and dictates the need for iron supplementation. **Mnemonic:** **IRON FIRST** — In CKD anemia, Iron repletion must precede ESA therapy to maximize erythropoietic response and minimize ESA resistance. ## Why Not the Other Options - **Option 0 (Iron alone, no ESA):** Iron repletion alone is insufficient in Stage 4 CKD; EPO deficiency is the primary driver of anemia and requires ESA. - **Option 2 (Immediate transfusion):** Transfusion is reserved for symptomatic anemia with Hb < 7 g/dL or acute bleeding; this patient is stable and can be managed medically. - **Option 3 (Defer ESA until PTH controlled):** PTH control is important for CKD-MBD but does not take priority over anemia management. ESA and mineral management proceed in parallel.